JCVI is acutely aware of the burden and severity of meningococcal meningitis and septicaemia in the UK and has always recognised the need to fully explore the potential for its prevention through immunisation. This statement sets out the conclusions of the JCVI regarding its deliberations on the cost-effectiveness of using serogroup B meningococcal (MenB) vaccine in the UK, both routinely in infants and/or adolescents and in at risk groups. This statement follows extensive discussion, which the Committee believes was necessary to ensure the most robust conclusion possible was reached. The Committee is of the opinion that its deliberations have taken into account the views and comments received, and are based on the most up to date and complete scientific evidence on MenB disease and the MenB vaccine Bexsero®. The health economic analyses undertaken comply with the methodology of National Institute of Health and Care Excellence (NICE) and appropriate NICE guidance.
- Recommendation
- Europe
- United Kingdom
- Meningococcal disease
